By Eric D. Peterson, MD, MPH, FAHA, Committee on Scientific Sessions Program Chair
It’s “Wear Red Day!” If you packed a red shirt, tie, dress or blouse, today’s the day to wear it to show your support for the AHA’s mission to raise awareness of heart disease in women.
The scientific program continues today with three Late-Breaking Science sessions, beginning with “Late-Breaking Science in Prevention” at 9 a.m. This session will feature a large primary prevention trial, REAL-CAD, as well as the latest results from the REVEAL, FOURIER and CANTOS trials.
At 10:45 a.m. during the day’s second Late-Breaking Science Session, “Latest Insights into Hypertension Management,” investigators will present results from the Chinese BP, SPRINT and GATEWAY trials.
The final Late-Breaking Science Session of the day, “Sweet Spot in Cardiometabolic Care,” begins at 3:45 p.m. and will include results from CANVAS, EXSCEL, EMPA-REG OUTCOME and a large metabolics registry, BiomarCaRE.
The highlight of the day is the release of the highly anticipated 2017 Hypertension Clinical Practice Guidelines at 2 p.m. during a Main Event session in Hall D, Main Building. Several sessions today will highlight the main recommendations and how they should impact current clinical care.
Today’s schedule also includes two Frontiers in Science summits, each featuring a full day of sessions. The Arrhythmia Research Summit begins at 9 a.m. in Ballroom B, 3rd Level, Main Building, and will cover the latest research and therapeutic innovations in arrhythmia mechanisms, diagnosis and management. The Thrombosis Summit begins at 10:45 a.m. in room 225ABC, ACC North, and will explore emerging therapies and the most recent progress in thrombosis research.
Also taking place today is a special HealthTech Summit featuring a daylong series of sessions covering the latest innovations in digital healthcare solutions and health information technology. The program begins with a Main Event session at 9 a.m. in Hall D titled “Technology and Healthcare: The Road Ahead.” It will feature a panel of speakers representing some of Silicon Valley’s foremost leaders in health technology, including GE Ventures, Microsoft, Qualcomm and Verily Life Sciences (formerly Google Life Sciences).
Always a highlight of Scientific Sessions are the “Best of AHA Specialty Conferences” sessions, which feature some of the top basic and clinical science abstracts presented at various specialty meetings in the past year. This year’s program includes six specialty conference sessions featuring abstracts from the 2017 ATVB/PVD, BCVS, EPI/Lifestyle, Hypertension, QCOR and ISC conferences. All of the sessions begin at 10:30 a.m.
That’s just a taste of what’s offered on a day packed with programming. Be sure to check the Final Program and the Mobile Meeting Guide for the complete schedule, including the times and locations of today’s sessions, events and activities.
Late-Breaking Science II: Late-Breaking Science in Prevention
LBS.02 | 9-10:15 a.m. Monday | Ballroom CD, 3rd Level, Main Building
|REAL-CAD — Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients with Stable Coronary Artery Disease||The REAL-CAD trial evaluated the efficacy of high-intensity pitavastatin therapy in patients with stable coronary artery disease in a relatively low-risk population.|
|REVEAL — Effects of Anacetrapib on the Incidence of New-onset Diabetes Mellitus and on Vascular Events in People with Diabetes||The HPS3/TIMI55-REVEAL trial evaluated the safety and efficacy of adding anacetrapib to an effective statin regimen in people with pre-existing cardiovascular disease.|
|FOURIER-PAD — Evolocumab and Outcomes in Patients with Peripheral Artery Disease||FOURIER-PAD evaluated the benefit of achieving very low LDL-C in patients with peripheral artery disease.|
|FOURIER-MI — Clinical Benefit of Evolocumab in Patients with a History of MI: An Analysis from FOURIER||FOURIER-MI sought to identify subsets of prior MI patients that derive greater clinical risk reduction with evolocumab.|
|CANTOS — Residual Inflammatory Risk and Residual Cholesterol Risk: Critical Analysis from the CANTOS Trial||CANTOS tested whether reducing inflammation among men and women who have had a prior myocardial infarction can reduce the risk of future cardiovascular events.|
Late-Breaking Science III: Latest Insights into Hypertension Management
LBS.03 | 10:45 a.m.-Noon Monday | Main Event I, Hall D, Main Building
|Chinese BP Trial — Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality||The Chinese BP trial evaluated the time at blood pressure target and the risk of cardiovascular diseases and mortality.|
|SPRINT — Blood Pressure Measurement in the Systolic Blood Pressure Intervention Trial||This SPRINT trial update evaluated attended versus unattended BP measurements to determine whether the BP technique usually employed at clinical sites was associated with a difference in BP values or overtreatment.|
|GATEWAY — Effects of Bariatric Surgery in Obese Patients with Hypertension||GATEWAY evaluated the impact of bariatric surgery on blood pressure and antihypertensive drug withdrawn.|
Late-Breaking Science IV: Sweet Spot in Cardiometabolic Care
LBS.04 | 3:45-5 p.m. Monday | Ballroom CD, 3rd Level, Main Building
|CANVAS — Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results from the CANVAS Program||This CANVAS trial update evaluated canagliflozin for the comparative effects among participants with and without a history of CV disease.|
|EXSCEL — Effect of Exenatide Once-Weekly on Clinical Outcomes in Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: Insights from the EXSCEL Trial||This trial evaluated the safety and efficacy of exenatide once weekly in a broad population of DM patients and the present results will detail the findings in the population with a prior CV event with a deeper dive into the CV outcomes.|
|EMPA-REG OUTCOME — Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial||This trial assessed the effects of empagliflozin versus placebo in addition to standard of care on cardiovascular morbidity and mortality in patients with Type 2 diabetes and established CV disease.|
|BiomarCaRE — Serum Metabolomic Profiles Predict Coronary Heart Disease in the General Population – The Biomarcare Consortium||This trial assessed the risk prediction capability of metabolites for incident CHD in the general population, addressing the environmental and genetic factors that reflect the heterogeneity of coronary heart disease.|